KKR-backed Biosynth Carbosynth acquires Vivitide
KKR closes its previously-announced acquisition of Biosynth Carbosynth and announces Biosynth's acquisition of vivitide.
Investment firm KKR has closed its acquisition of UK life sciences company Biosynth Carbosynth, and announced Biosynth's acquisition of vivitide, which provides custom peptides and antibodies for the biotech industry.
Previous vivitide owner Ampersand Capital Partners will become a minority stakeholder in the combined entity. KKR and Ampersand say they plan to accelerate the company’s geographic expansion, broaden its capabilities and expand its product portfolio.
KKR utilized a $4 billion strategic growth fund focused on high-growth health care companies to invest in Biosynth Carbosynth. Company leadership believe the move will position Biosynth Carbosynth as a premium global platform serving high-growth end markets in the life sciences.
Speaking on the acquisition, Biosynth Carbosynth CEO Dr. Urs Spitz said the deal marks an “important milestone” in the company’s journey, adding that Biosynth will “benefit greatly from vivitide’s strong U.S. presence, complementary portfolio of products and services, and entrepreneurial culture.”
Vivitide CEO Dr. Martina Diekmann said she was proud to join forces with Biosynth, noting that the acquisition will allow an acceleration of growth and expanded product offering.
Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.